2.41 USD
+0.01 (+0.42%)
2.44 USD
+0.03 (+1.24%)
We assign a fundamental rating of 1 out of 10 to EDIT. EDIT was compared to 534 industry peers in the Biotechnology industry. Both the profitability and financial health of EDIT have multiple concerns. EDIT does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
In the past year EDIT has reported negative net income.
In the past year EDIT has reported a negative cash flow from operations.
In the past 5 years EDIT always reported negative net income.
EDIT had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -99.05%, EDIT is doing worse than 74.34% of the companies in the same industry.
EDIT has a Return On Equity of -1485.43%. This is amonst the worse of the industry: EDIT underperforms 81.84% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -99.05% | ||
| ROE | -1485.43% | ||
| ROIC | N/A |
ROA(3y)-47.65%
ROA(5y)-38.33%
ROE(3y)-93.86%
ROE(5y)-69.16%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
EDIT does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
EDIT does not have a ROIC to compare to the WACC, probably because it is not profitable.
EDIT has more shares outstanding than it did 1 year ago.
The number of shares outstanding for EDIT has been increased compared to 5 years ago.
The debt/assets ratio for EDIT is higher compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of -11.55, we must say that EDIT is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of EDIT (-11.55) is worse than 75.47% of its industry peers.
EDIT has a Debt/Equity ratio of 4.02. This is a high value indicating a heavy dependency on external financing.
Looking at the Debt to Equity ratio, with a value of 4.02, EDIT is doing worse than 81.27% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 4.02 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -11.55 |
ROIC/WACCN/A
WACC8.37%
2.3 Liquidity
A Current Ratio of 2.86 indicates that EDIT has no problem at all paying its short term obligations.
EDIT has a Current ratio of 2.86. This is in the lower half of the industry: EDIT underperforms 64.79% of its industry peers.
A Quick Ratio of 2.86 indicates that EDIT has no problem at all paying its short term obligations.
EDIT has a Quick ratio of 2.86. This is in the lower half of the industry: EDIT underperforms 63.11% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.86 | ||
| Quick Ratio | 2.86 |
3. Growth
3.1 Past
The Earnings Per Share has been growing slightly by 7.03% over the past year.
Looking at the last year, EDIT shows a very negative growth in Revenue. The Revenue has decreased by -24.90% in the last year.
EDIT shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 9.50% yearly.
EPS 1Y (TTM)7.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%62.67%
Revenue 1Y (TTM)-24.9%
Revenue growth 3Y8.16%
Revenue growth 5Y9.5%
Sales Q2Q%12265.57%
3.2 Future
EDIT is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 10.34% yearly.
EDIT is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -16.97% yearly.
EPS Next Y27.22%
EPS Next 2Y27.6%
EPS Next 3Y17.53%
EPS Next 5Y10.34%
Revenue Next Year-49.61%
Revenue Next 2Y-40.95%
Revenue Next 3Y-24.94%
Revenue Next 5Y-16.97%
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for EDIT. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for EDIT. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as EDIT's earnings are expected to grow with 17.53% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.6%
EPS Next 3Y17.53%
5. Dividend
5.1 Amount
No dividends for EDIT!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
2.41
+0.01 (+0.42%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners49.4%
Inst Owner Change2.22%
Ins Owners0.22%
Ins Owner Change-0.09%
Market Cap235.26M
Revenue(TTM)46.38M
Net Income(TTM)-199.84M
Analysts73
Price Target4.03 (67.22%)
Short Float %9.67%
Short Ratio3.17
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-28.23%
Min EPS beat(2)-63.79%
Max EPS beat(2)7.33%
EPS beat(4)1
Avg EPS beat(4)-40.18%
Min EPS beat(4)-63.79%
Max EPS beat(4)7.33%
EPS beat(8)3
Avg EPS beat(8)-15.9%
EPS beat(12)6
Avg EPS beat(12)-7.53%
EPS beat(16)10
Avg EPS beat(16)-3.06%
Revenue beat(2)2
Avg Revenue beat(2)78.71%
Min Revenue beat(2)47.32%
Max Revenue beat(2)110.1%
Revenue beat(4)3
Avg Revenue beat(4)174.34%
Min Revenue beat(4)-6.91%
Max Revenue beat(4)546.84%
Revenue beat(8)4
Avg Revenue beat(8)133.14%
Revenue beat(12)7
Avg Revenue beat(12)116.99%
Revenue beat(16)10
Avg Revenue beat(16)100.47%
PT rev (1m)-1.25%
PT rev (3m)1.57%
EPS NQ rev (1m)-11.34%
EPS NQ rev (3m)-10.58%
EPS NY rev (1m)0%
EPS NY rev (3m)0.32%
Revenue NQ rev (1m)0.94%
Revenue NQ rev (3m)0.98%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.04%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 5.07 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 17.49 | ||
| P/tB | 17.49 | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.38
EYN/A
EPS(NY)-1.07
Fwd EYN/A
FCF(TTM)-1.85
FCFYN/A
OCF(TTM)-1.84
OCFYN/A
SpS0.48
BVpS0.14
TBVpS0.14
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -99.05% | ||
| ROE | -1485.43% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-47.65%
ROA(5y)-38.33%
ROE(3y)-93.86%
ROE(5y)-69.16%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.23
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 4.02 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 18.57% | ||
| Cap/Sales | 2.34% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.86 | ||
| Quick Ratio | 2.86 | ||
| Altman-Z | -11.55 |
F-Score2
WACC8.37%
ROIC/WACCN/A
Cap/Depr(3y)98.25%
Cap/Depr(5y)126.71%
Cap/Sales(3y)18.09%
Cap/Sales(5y)18.68%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)7.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%62.67%
EPS Next Y27.22%
EPS Next 2Y27.6%
EPS Next 3Y17.53%
EPS Next 5Y10.34%
Revenue 1Y (TTM)-24.9%
Revenue growth 3Y8.16%
Revenue growth 5Y9.5%
Sales Q2Q%12265.57%
Revenue Next Year-49.61%
Revenue Next 2Y-40.95%
Revenue Next 3Y-24.94%
Revenue Next 5Y-16.97%
EBIT growth 1Y47.63%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year28.77%
EBIT Next 3Y16.98%
EBIT Next 5YN/A
FCF growth 1Y-15.65%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-18.01%
OCF growth 3YN/A
OCF growth 5YN/A
EDITAS MEDICINE INC / EDIT FAQ
Can you provide the ChartMill fundamental rating for EDITAS MEDICINE INC?
ChartMill assigns a fundamental rating of 1 / 10 to EDIT.
What is the valuation status of EDITAS MEDICINE INC (EDIT) stock?
ChartMill assigns a valuation rating of 0 / 10 to EDITAS MEDICINE INC (EDIT). This can be considered as Overvalued.
How profitable is EDITAS MEDICINE INC (EDIT) stock?
EDITAS MEDICINE INC (EDIT) has a profitability rating of 0 / 10.
What is the financial health of EDITAS MEDICINE INC (EDIT) stock?
The financial health rating of EDITAS MEDICINE INC (EDIT) is 2 / 10.